Business Context and Reporting Period
This Form 8-K, dated July 8, 2022, is a supplemental disclosure filed by Healthcare Trust of America, Inc. (HTA) and Healthcare Trust of America Holdings, LP (HTA OP) regarding their proposed merger with Healthcare Realty Trust Incorporated (HR). The filing responds to shareholder lawsuits alleging that the Definitive Proxy Statement was materially incomplete. The companies voluntarily provided additional financial analyses to address these claims without admitting liability. A special meeting of HTA stockholders to vote on the merger is scheduled for July 15, 2022.
Key Financial Metrics and Valuation
The filing does not report standard operating metrics such as revenue, profit, or cash flow for a specific reporting period. Instead, it provides valuation ranges derived from financial advisor analyses (Citi and J.P. Morgan) to support the merger consideration.
- Implied Per Share Equity Value (HTA): $29.75 to $35.50 (based on J.P. Morgan's transaction analysis).
- Implied Per Share Equity Value (HR): $27.86 to $37.63 (based on Citi's DCF analysis).
- Implied Per Share Equity Value (HTA - DCF): $28.51 to $36.49 (based on Citi's DCF analysis).
- Implied Exchange Ratio Range: 0.880x to 1.589x (compared to the agreed 1.0000x ratio).
- Combined Company Implied Value: $25.69 to $33.73 per share (under base case assumptions).
- Analyst Price Targets (HR): Low $30.28, High $38.00, Mean $34.04.
- Analyst Price Targets (HTA): Low $31.86, High $38.00, Mean $35.76.
Material Changes and Litigation
The primary material event is the filing of five shareholder lawsuits (three against HR and two against HTA) challenging the merger proxy statements. These lawsuits allege violations of Sections 14(a) and 20(a) of the Exchange Act and SEC Rule 14a-9, claiming the proxy statements were materially misleading. In response, the companies have supplemented the proxy statement with additional valuation data, including public trading multiples, selected transaction analyses, and discounted cash flow (DCF) analyses. The filing explicitly states that these supplemental disclosures do not alter the merger consideration or the timing of the shareholder vote.
Guidance, Risks, and Management Commentary
Management Commentary: Management believes the legal claims are without merit and that no supplemental disclosure was legally required. However, they chose to provide the additional information to avoid litigation delays and costs. The merger is expected to be led by the HR management team.
Risks and Contingencies:
- Litigation Risk: Additional lawsuits may be filed, and existing suits seek to enjoin the merger or rescind it.
- Transaction Risk: Risks include failure to obtain shareholder approval, inability to secure financing, and integration challenges.
- Market Risk: Potential decline in stock price if perceived benefits are not realized rapidly.
- Operational Risk: Risks related to tenant insolvency, interest rate increases, and general economic conditions.
Financial Advisor Fees: HR agreed to pay Citi an aggregate fee of $20.0 million ($2.0 million upon delivery of the opinion, balance contingent on consummation). Citi may also receive approximately $2 million in fees for participating in credit facilities for the combined company.
Investor Verification Checklist
- Verify the status of the five pending shareholder lawsuits and any court rulings regarding injunctions.
- Confirm the outcome of the HTA special meeting of stockholders scheduled for July 15, 2022.
- Review the full Definitive Proxy Statement and the Supplemental Disclosure to understand the specific valuation assumptions (e.g., exit cap rates of 4.75%–5.50% and discount rates of 7.00%–8.02%).
- Monitor the combined company's ability to secure financing and the potential impact of the $20 million advisory fee on transaction costs.
- Check for any updates on the resignation of HTA's former CEO and the transition to HR's management team.